Prognostic impact of β-2-microglobulin expression in colorectal cancers stratified by mismatch repair status

Journal of Clinical Pathology

Volumn 65, Issue 11, 2012, Pages 996-1002

  Koelzer, Viktor Hendrik ^a   Baker, Kristi ^b   Kassahn, Daniela ^a   Baumhoer, Daniel ^c   Zlobec, Inti ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CD16 ANTIGEN; CD163 ANTIGEN; CD20 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD45RO ANTIGEN; CD56 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; GRANZYME B; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERFERON REGULATORY FACTOR 4; TRANSCRIPTION FACTOR FOXP3; TRYPTASE;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MISMATCH REPAIR; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BETA 2-MICROGLOBULIN; COLORECTAL NEOPLASMS; DNA MISMATCH REPAIR; FEMALE; HUMANS; INTESTINAL MUCOSA; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; OBSERVER VARIATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SURVIVAL RATE; SWITZERLAND; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84867909821     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2012-200742     Document Type: Article

References (32)

1. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010;138:2073-87.
2. Pino MS, Chung DC. The chromosomal instability pathway in colon cancer. Gastroenterology 2010;138:2059-72.
3. Soreide K, Janssen EA, Soiland H, et al. Microsatellite instability in colorectal cancer. Br J Surg 2006;93:395-406.
4. Jenkins MA, Hayashi S, O'Shea AM, et al. Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology 2007;133:48-56. (Pubitemid 47039240)
5. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993;260:816-19. (Pubitemid 23167612)
6. Schwitalle Y, Kloor M, Eiermann S, et al. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology 2008;134:988-97. (Pubitemid 351459601)
7. Speetjens FM, Lauwen MM, Franken KL, et al. Prediction of the immunogenic potential of frameshift-mutated antigens in microsatellite instable cancer. Int J Cancer 2008;123:838-45. (Pubitemid 352032410)
8. Cabrera CM, Jimenez P, Cabrera T, et al. Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: beta2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors. Tissue Antigens 2003;61:211-19. (Pubitemid 36605543)
9. Kloor M, Michel S, Buckowitz B, et al. Beta2-microglobulin mutations in microsatellite unstable colorectal tumors. Int J Cancer 2007;121:454-8. (Pubitemid 46917717)
10. Yamamoto H, Yamashita K, Perucho M. Somatic mutation of the beta2-microglobulin gene associates with unfavorable prognosis in gastrointestinal cancer of the microsatellite mutator phenotype. Gastroenterology 2001;120:1565-7. (Pubitemid 32322336)
11. Dierssen JW, de Miranda NF, Ferrone S, et al. HNPCC versus sporadic microsatellite-unstable colon cancers follow different routes toward loss of HLA class I expression. BMC Cancer 2007;7:33.
12. Tikidzhieva A, Benner A, Michel S, et al. Microsatellite instability and Beta2-Microglobulin mutations as prognostic markers in colon cancer: results of the FOGT-4 trial. Br J Cancer 2012;106:1239-45.
13. Chen CH, Su CY, Chien CY, et al. Overexpression of beta2-microglobulin is associated with poor survival in patients with oral cavity squamous cell carcinoma and contributes to oral cancer cell migration and invasion. Br J Cancer 2008;99:1453-61.
14. Josson S, Nomura T, Lin JT, et al. beta2-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells. Cancer Research 2011;71:2600-10.
15. Nomura T, Huang WC, Zhau HE, et al. Beta2-microglobulin promotes the growth of human renal cell carcinoma through the activation of the protein kinase A, cyclic AMP-responsive element-binding protein, and vascular endothelial growth factor axis. Clin Cancer Res 2006;12:7294-305. (Pubitemid 46095401)
16. Bataille R, Durie BG, Grenier J. Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging. Br J Haematol 1983;55:439-47. (Pubitemid 14242342)
17. Gatto S, Ball G, Onida F, et al. Contribution of beta-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS). Blood 2003;102:1622-5. (Pubitemid 37022552)
18. Gross M, Top I, Laux I, et al. Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer. Clin Cancer Res 2007;13:1979-86. (Pubitemid 46649863)
19. Zlobec I, Terracciano L, Tornillo L, et al. Role of RHAMM within the hierarchy of well-established prognostic factors in colorectal cancer. Gut 2008;57:1413-19.
20. de la Chapelle A, Hampel H. Clinical relevance of microsatellite instability in colorectal cancer. J Clin Oncol 2010;28:3380-7.
21. Bernal M, Concha A, Saenz-Lopez P, et al. Leukocyte infiltrate in gastrointestinal adenocarcinomas is strongly associated with tumor microsatellite instability but not with tumor immunogenicity. Cancer Immunol Immunother 2011;60(6):869-82.
22. Kloor M, Michel S, von Knebel, et al. Immune evasion of microsatellite unstable colorectal cancers. Int J Cancer 2010;127:1001-10.
23. Menon AG, Tollenaar RA, van de Velde CJ, et al. p53 and HLA class-I expression are not down-regulated in colorectal cancer liver metastases. Clin Exp Metastasis 2004;21:79-85. (Pubitemid 38365661)
24. Menon AG, Morreau H, Tollenaar RA, et al. Down-regulation of HLA-A expression correlates with a better prognosis in colorectal cancer patients. Lab Invest 2002;82:1725-33. (Pubitemid 35462985)
25. Blum C, Graham A, Yousefzadeh M, et al. The expression ratio of Map7/B2M is prognostic for survival in patients with stage II colon cancer. Int J Oncol 2008;33:579-84.
26. Menon AG, Janssen-van Rhijn CM, Morreau H, et al. Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab Invest 2004;84:493-501. (Pubitemid 41656477)
27. Sandel MH, Speetjens FM, Menon AG, et al. Natural killer cells infiltrating colorectal cancer and MHC class I expression. Mol Immunol 2005;42:541-6. (Pubitemid 39655966)
28. Kloor M, Becker C, Benner A, et al. Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers. Cancer Res 2005;65:6418-24. (Pubitemid 40994430)
29. Maleno I, Cabrera CM, Cabrera T, et al. Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Immunogenetics 2004;56:244-53. (Pubitemid 39119279)
30. Kasajima A, Sers C, Sasano H, et al. Down-regulation of the antigen processing machinery is linked to a loss of inflammatory response in colorectal cancer. Hum Pathol 2010;41:1758-69.
31. Deschoolmeester V, Baay M, Van Marck E, et al. Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients. BMC Immunol 2010;11:19.
32. McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97:1180-4. (Pubitemid 41258223)